The higher occurrence of dyskinesia suggests that GBA carriers may be more sensitive to medications and genetic assessment in the appropriate patient should be taken into consideration (5, 9, 36) (similarly to the levodopa sensitivity and more frequent dyskinesia resulting in small levodopa doses being used for parkin mutations carriers). The gene discussed is PRKN; the disease is drug-induced dyskinesia.